Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2018	FY 2017	2016 - 2020
Period Ending	Aug '25 Aug 12, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	2016 - 2020
Market Capitalization	5,433	5,280	4,668	4,340	-	-	Upgrade
Market Cap Growth	16.98%	13.10%	7.56%	-	-	-	Upgrade
Enterprise Value	3,238	2,901	2,733	-	-	-	Upgrade
Last Close Price	1418.00	1378.00	1170.42	1070.56	-	-	Upgrade
PE Ratio	11.74	11.26	11.40	12.08	-	-	Upgrade
PS Ratio	1.98	1.98	2.02	1.99	-	-	Upgrade
PB Ratio	1.99	1.86	1.97	2.24	-	-	Upgrade
P/TBV Ratio	2.10	1.96	1.98	2.27	-	-	Upgrade
P/FCF Ratio	-	9.81	12.65	12.75	-	-	Upgrade
P/OCF Ratio	-	8.79	10.18	9.77	-	-	Upgrade
EV/Sales Ratio	1.18	1.09	1.18	-	-	-	Upgrade
EV/EBITDA Ratio	4.53	4.03	4.05	-	-	-	Upgrade
EV/EBIT Ratio	5.11	4.55	4.61	-	-	-	Upgrade
EV/FCF Ratio	-	5.39	7.41	-	-	-	Upgrade
Debt / Equity Ratio	-	0.02	-	-	-	-	Upgrade
Debt / EBITDA Ratio	-	0.08	-	-	-	-	Upgrade
Debt / FCF Ratio	-	0.11	-	-	-	-	Upgrade
Asset Turnover	0.92	0.86	0.90	-	1.45	1.61	Upgrade
Inventory Turnover	564.30	487.85	515.39	-	31.40	38.58	Upgrade
Quick Ratio	6.31	5.38	5.89	4.58	1.37	1.15	Upgrade
Current Ratio	6.47	5.52	6.07	4.70	3.39	2.54	Upgrade
Return on Equity (ROE)	17.77%	17.97%	19.00%	-	18.41%	25.38%	Upgrade
Return on Assets (ROA)	13.21%	12.83%	14.36%	-	12.61%	17.05%	Upgrade
Return on Capital (ROIC)	15.20%	15.11%	17.18%	-	16.63%	23.19%	Upgrade
Return on Capital Employed (ROCE)	23.20%	22.00%	25.00%	26.90%	24.30%	32.80%	Upgrade
Earnings Yield	8.52%	8.88%	8.77%	8.28%	-	-	Upgrade
FCF Yield	-	10.19%	7.90%	7.84%	-	-	Upgrade
Dividend Yield	1.32%	1.31%	-	-	-	-	Upgrade
Buyback Yield / Dilution	-0.11%	-0.24%	1.18%	-	-	-	Upgrade
Total Shareholder Return	1.20%	1.07%	1.18%	-	-	-	Upgrade

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.